Abstract
Background This study evaluates the cost-effectiveness of extending the Dutch influenza vaccination programme for elderly and clinical risk groups to include paediatric influenza vaccination, taking indirect protection into account.
Methods An age-structured dynamic transmission model was used that was calibrated to influenza-associated GP visits over four seasons (2010/11 to 2013/14). The clinical and economic impact of different paediatric vaccination strategies were compared over 20 years, varying the targeted age range, the vaccine type for children and the vaccine type for elderly and clinical risk groups. Outcome measures include averted symptomatic infections and deaths, societal costs and quality-adjusted life years (QALYs), incremental cost-effectiveness ratios, and net health benefits (NHBs), using a willingness-to-pay threshold of €20,000 per QALY gained.
Results At an assumed coverage of 50%, adding vaccination of 2- to 17-year-olds with quadrivalent-live-attenuated influenza vaccine (Q-LAIV) to the current influenza vaccination programme was estimated to avert on average 406,270 symptomatic cases and 83 deaths per season compared to vaccination of elderly and risk groups with trivalent inactivated vaccine (TIV), and was cost-saving (cumulative 20-year savings of 36,396 QALYs and €1,680 million; NHB: 120,411 QALYs). This strategy dominated paediatric vaccination strategies targeting 2- to 6-year-olds or 2- to 12-year-olds, or paediatric vaccination strategies with TIV. The highest NHB was obtained when 2- to 17-year-olds were vaccinated with Q-LAIV and existing target groups switched from TIV to quadrivalent inactivated vaccine (NHB: 132,907 QALYs).
Conclusion Modelling indicates that paediatric influenza vaccination reduces the disease burden of influenza substantially and is cost-saving.
Competing Interest Statement
This study was sponsored by AstraZeneca. The funding source had no involvement in the study design or collection, analysis, and interpretation of data. The PhD positions of PTdB and FCKD at the University of Groningen have been supported by grants from various pharmaceutical companies, including those developing, producing and marketing influenza vaccines. PTdB is currently employed at the Dutch National Institute for Public Health and the Environment (RIVM); this work is not on behalf of the RIVM. JCW and MJP have received grants and honoraria from various pharmaceutical companies, including those developing, producing and marketing influenza vaccines. RP has participated as a member of AstraZeneca advisory boards and received funding for research projects.
Funding Statement
This study was sponsored by AstraZeneca. The funding source had no involvement in the study design or collection, analysis, and interpretation of data. The PhD positions of PTdB and FCKD at the University of Groningen have been supported by grants from various pharmaceutical companies, including those developing, producing and marketing influenza vaccines. PTdB is currently employed at the Dutch National Institute for Public Health and the Environment (RIVM); this work is not on behalf of the RIVM. JCW and MJP have received grants and honoraria from various pharmaceutical companies, including those developing, producing and marketing influenza vaccines. RP has participated as a member of AstraZeneca advisory boards and received funding for research projects.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All relevant data are within the paper. Further details are available from the first author on reasonable request.
